Oxidative stress and Parkinson's disease

Handbook of Clinical Neurology

Volumn 83, Issue , 2007, Pages 507-520

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649329442     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)83024-7     Document Type: Review

References (198)

1. Agid Y., Javoy-Agid F., and Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders 2 (1986), Butterworths, London 166-230
2. Ahlskog J.E. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 20 (2005) 271-282
3. Alam Z.I., Daniel S.E., Lees A.J., et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69 (1997) 1326-1329
4. Alam Z.I., Jenner A., Daniel S.E., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69 (1997) 1196-1203
5. Almeida A., Heales S.J., Bolanos J.P., et al. Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion. Brain Res 790 (1998) 209-216
6. Ambani L.M., Van Woert M.H., and Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 32 (1975) 114-118
7. Aoyama K., Matsubara K., and Kobayashi S. Aging and oxidative stress in progressive supranuclear palsy. Eur J Neurol 13 (2006) 89-92
8. Banati R.B., Daniel S.E., and Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13 (1998) 221-227
9. Barcia C., Bautista V., Sanchez-Bahillo A., et al. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112 (2005) 1237-1248
10. Barker J.E., Heales S.J., Cassidy A., et al. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res 716 (1996) 118-122
11. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44 (1998) S110-S114
12. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
13. Betarbet R., Sherer T.B., MacKenzie G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
14. Bezard E. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. Lancet Neurol 2 (2003) 393
15. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26 (2003) 215-221
16. Bindoff L.A., Birch-Machin M.A., Cartlidge N.E., et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 104 (1991) 203-208
17. Blandini F., Greenamyre J.T., and Nappi G. The role of glutamate in the pathophysiology of Parkinson's disease. Funct Neurol 11 (1996) 3-15
18. Bonifati V., Rizzu P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
19. Bonneh-Barkay D., Langston W.J., and Di Monte D.A. Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal 7 (2005) 649-653
20. Braak H., Ghebremedhin E., Rub U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 (2004) 121-134
21. Budka H. Neuropathology of prion diseases. Br Med Bull 66 (2003) 121-130
22. Calabrese V., Lodi R., Tonon C., et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 233 (2005) 145-162
23. Canet-Aviles R.M., Wilson M.A., Miller D.W., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101 (2004) 9103-9108
24. Cantuti-Castelvetri I., Keller-McGandy C.E., Albers D.S., et al. Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res 930 (2002) 170-181
25. Carri M.T., Ferri A., Cozzolino M., et al. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 61 (2003) 365-374
26. Castellani R.J., Perry G., Siedlak S.L., et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319 (2002) 25-28
27. Chung K.K., Thomas B., Li X., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 (2004) 1328-1331
28. Cleeter M.W., Cooper J.M., and Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58 (1992) 786-789
29. Clement M.V., Long L.H., Ramalingam J., et al. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 81 (2002) 414-421
30. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45 (1987) 119-125
31. Cohen G., and Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249 (1974) 2447-2452
32. Cohen G., and Spina M.B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26 (1989) 689-690
33. Cookson M.R. The biochemistry of Parkinson's disease. Annu Rev Biochem 74 (2005) 29-52
34. dam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 7 (2005) 1140-1149
35. Dexter D., Carter C., Agid F., et al. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2 (1986) 639-640
36. Dexter D.T., Wells F.R., Agid F., et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987) 1219-1220
37. Dexter D.T., Carter C.J., Wells F.R., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52 (1989) 381-389
38. Dexter D.T., Wells F.R., Lees A.J., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52 (1989) 1830-1836
39. Dexter D.T., Carayon A., Vidailhet M., et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55 (1990) 16-20
40. Dexter D.T., Carayon A., Javoy-Agid F., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 Pt 4 (1991) 1953-1975
41. Dexter D.T., Ward R.J., Wells F.R., et al. Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol 32 (1992) 591-593
42. Dexter D.T., Holley A.E., Flitter W.D., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9 (1994) 92-97
43. Di Monte D., Sandy M.S., Ekstrom G., et al. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem Biophys Res Commun 137 (1986) 303-309
44. Diguet E., Gross C.E., Bezard E., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 62 (2004) 158-159
45. Enochs W.S., Sarna T., Zecca L., et al. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neural Transm Park Dis Dement Sect 7 (1994) 83-100
46. Faucheux B.A., Hirsch E.C., Villares J., et al. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60 (1993) 2338-2341
47. Faucheux B.A., Herrero M.T., Villares J., et al. Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. Brain Res 691 (1995) 115-124
48. Faucheux B.A., Hauw J.J., Agid Y., et al. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 749 (1997) 170-174
49. Faucheux B.A., Martin M.E., Beaumont C., et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 83 (2002) 320-330
50. Faucheux B.A., Martin M.E., Beaumont C., et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86 (2003) 1142-1148
51. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
52. Ferger B., Rose S., Jenner A., et al. 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. Neuroreport 12 (2001) 1155-1159
53. Ferrante R.J., Hantraye P., Brouillet E., et al. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 823 (1999) 177-182
54. Fessel J.P., Hulette C., Powell S., et al. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 85 (2003) 645-650
55. Fitzmaurice P.S., Ang L., Guttman M., et al. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord 18 (2003) 969-976
56. Floor E., and Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70 (1998) 268-275
57. Fukae J., Takanashi M., Kubo S., et al. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol (Berl) 109 (2005) 256-262
58. Gandhi S., and Wood N.W. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 14 (2005) 2749-2755 Spec No 2
59. Giasson B.I., Duda J.E., Murray I.V., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
60. Gibb W.R., Fearnley J.M., and Lees A.J. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. Adv Neurol 53 (1990) 31-34
61. Gibson G.E., Park L.C., Sheu K.F., et al. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem Int 36 (2000) 97-112
62. Gibson G.E., Kingsbury A.E., Xu H., et al. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. Neurochem Int 43 (2003) 129-135
63. Gilks W.P., bou-Sleiman P.M., Gandhi S., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
64. Gloeckner C.J., Kinkl N., Schumacher A., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15 (2006) 223-232
65. Goldwurm S., Di F.A., Simons E.J., et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42 (2005) e65
66. Gomez-Tortosa E., Gonzalo I., Newell K., et al. Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathol (Berl) 103 (2002) 495-500
67. Good P.F., Olanow C.W., and Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 593 (1992) 343-346
68. Good P.F., Hsu A., Werner P., et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57 (1998) 338-342
69. Gotz M.E., Gerstner A., Harth R., et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm 107 (2000) 41-48
70. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14 (1978) 633-643
71. Graham D.G. On the origin and significance of neuromelanin. Arch Pathol Lab Med 103 (1979) 359-362
72. Graham D.G., Tiffany S.M., Bell Jr. W.R., et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14 (1978) 644-653
73. Grau A.J., Willig V., Fogel W., et al. Assessment of plasma lactoferrin in Parkinson's disease. Mov Disord 16 (2001) 131-134
74. Greene J.C., Whitworth A.J., Andrews L.A., et al. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 14 (2005) 799-811
75. Gu M., Cooper J.M., Taanman J.W., et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44 (1998) 177-186
76. Gu M., Owen A.D., Toffa S.E., et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158 (1998) 24-29
77. Halliwell B., and Gutteridge J.M.C. Free Radicals in Biology and Medicine (1999), Oxford University Press, Oxford
78. Heikkila R.E., and Cohen G. In vivo generation of hydrogen peroxide from 6-hydroxydopamine. Experientia 28 (1972) 1197-1198
79. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
80. Hernandez D., Paisan R.C., Crawley A., et al. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389 (2005) 137-139
81. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
82. Hirsch E.C., Graybiel A.M., and Agid Y. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol Scand Suppl 126 (1989) 19-22
83. Hoglinger G.U., Feger J., Prigent A., et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84 (2003) 491-502
84. Hyun D.H., Lee M., Hattori N., et al. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 277 (2002) 28572-28577
85. Hyun D.H., Lee M.H., Halliwell B., et al. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J Neurochem 83 (2002) 360-370
86. Ihara Y., Nobukuni K., Takata H., et al. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27 (2005) 105-108
87. Iravani M.M., Haddon C.O., Rose S., et al. 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 1067 1 (2005) 256-262
88. Jellinger K. The pathology of parkinsonism. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders 2 (1987), Butterworths, London 124-165
89. Jellinger K. New developments in the pathology of Parkinson's disease. Adv Neurol 53 (1990) 1-16
90. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 136 (1991) 6-15
91. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146 (1993) 6-13
92. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 344 (1994) 796-798
93. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol Biol (Paris) 44 (1996) 57-64
94. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 Suppl 1 (1998) 24-34
95. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S26-S36
96. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
97. Jenner P., and Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol 44 (1998) S72-S84
98. Jenner P., Dexter D.T., Sian J., et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 Suppl (1992) S82-S87
99. Jiang H., Ren Y., Zhao J., et al. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13 (2004) 1745-1754
100. Kastner A., Hirsch E.C., Lejeune O., et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J Neurochem 59 (1992) 1080-1089
101. Keller J.N., Schmitt F.A., Scheff S.W., et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64 (2005) 1152-1156
102. Kikuchi A., Takeda A., Onodera H., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9 (2002) 244-248
103. Kim R.H., Smith P.D., Aleyasin H., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102 (2005) 5215-5220
104. Kish S.J., Morito C., and Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58 (1985) 343-346
105. Kortekaas R., Leenders K.L., van Oostrom J.C., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
106. Lee M.H., Hyun D., Halliwell B., et al. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76 (2001) 998-1009
107. Lee M.H., Hyun D.H., Jenner P., et al. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem 78 (2001) 32-41
108. Leveugle B., Faucheux B.A., Bouras C., et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol (Berl) 91 (1996) 566-572
109. Logroscino G., Marder K., Graziano J., et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 49 (1997) 714-717
110. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275 (2000) 38581-38588
111. Lyras L., Zeng B.Y., McKenzie G., et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 109 (2002) 53-67
112. Maguire-Zeiss K.A., Short D.W., and Federoff H.J. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Brain Res Mol Brain Res 134 (2005) 18-23
113. Mann V.M., Cooper J.M., Krige D., et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 Pt 2 (1992) 333-342
114. Mann V.M., Cooper J.M., Daniel S.E., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36 (1994) 876-881
115. Margaill I., Plotkine M., and Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med 39 (2005) 429-443
116. Mariani E., Polidori M.C., Cherubini A., et al. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827 (2005) 65-75
117. Marttila R.J., Lorentz H., and Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86 (1988) 321-331
118. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10 (2002) 119-127
119. McCormack A.L., Atienza J.G., Johnston L.C., et al. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93 (2005) 1030-1037
120. McGeer P.L., Itagaki S., Boyes B.E., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
121. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297 (2001) 191-194
122. McNaught K.S., Olanow C.W., Halliwell B., et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2 (2001) 589-594
123. McNaught K.S., Belizaire R., Jenner P., et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326 (2002) 155-158
124. McNaught K.S., Shashidharan P., Perl D.P., et al. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 16 (2002) 2136-2148
125. McNaught K.S., Belizaire R., Isacson O., et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 (2003) 38-46
126. Mena M.A., Pardo B., Casarejos M.J., et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7 (1992) 23-31
127. Michel P.P., and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26 (1990) 428-435
128. Michell A.W., Lewis S.J., Foltynie T., et al. Biomarkers and Parkinson's disease. Brain 127 (2004) 1693-1705
129. Migliore L., Petrozzi L., Lucetti C., et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
130. Migliore L., Fontana I., Colognato R., et al. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26 (2005) 587-595
131. Mitsumoto A., and Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 35 (2001) 885-893
132. Mitsumoto A., Nakagawa Y., Takeuchi A., et al. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 35 (2001) 301-310
133. Mizuno Y., Ohta S., Tanaka M., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163 (1989) 1450-1455
134. Mizuno Y., Matuda S., Yoshino H., et al. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35 (1994) 204-210
135. Moore D.J., West A.B., Dawson V.L., et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 (2005) 57-87
136. Moore D.J., Zhang L., Troncoso J., et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 14 (2005) 71-84
137. Morris C.M., and Edwardson J.A. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3 (1994) 277-282
138. Nakamura K., Bindokas V.P., Marks J.D., et al. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58 (2000) 271-278
139. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology 40 10 Suppl 3 (1990) 37-39 suppl 32-37
140. Olanow C.W. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32 Suppl (1992) S2-S9
141. Olanow C.W., and Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 20 Suppl 11 (2005) S3-S10
142. Olanow C.W., Agid Y., Mizuno Y., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 (2004) 997-1005
143. Paisan-Ruiz C., Jain S., Evans E.W., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
144. Palacino J.J., Sagi D., Goldberg M.S., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004) 18614-18622
145. Panov A., Dikalov S., Shalbuyeva N., et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 280 (2005) 42026-42035
146. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719-723
147. Paxinou E., Chen Q., Weisse M., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21 (2001) 8053-8061
148. Pearce R.K., Owen A., Daniel S., et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104 (1997) 661-677
149. Pennathur S., Jackson-Lewis V., Przedborski S., et al. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274 (1999) 34621-34628
150. Qian Z.M., and Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 27 (1998) 257-267
151. Rampello L., Butta V., Raffaele R., et al. Progressive supranuclear palsy: a systematic review. Neurobiol Dis 20 (2005) 179-186
152. Ramsay R.R., Kowal A.T., Johnson M.K., et al. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys 259 (1987) 645-649
153. Riederer P., Sofic E., Rausch W.D., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
154. Riederer P., Dirr A., Goetz M., et al. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol 32 Suppl (1992) S101-S104
155. Rodriguez M.C., Obeso J.A., and Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44 (1998) S175-S188
156. Saggu H., Cooksey J., Dexter D., et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53 (1989) 692-697
157. Sanchez-Ramos J., Overik E., and Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in the nigro-striatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197-204
158. Sato S., Mizuno Y., and Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64 (2005) 1081-1083
159. Schaller B. Prospects for the future: the role of free radicals in the treatment of stroke. Free Radic Biol Med 38 (2005) 411-425
160. Schapira A.H. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov Disord 9 (1994) 125-138
161. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
162. Schapira A.H., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
163. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142-2145
164. Schipper H.M., Bennett D.A., Liberman A., et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27 (2006) 252-261
165. Shimura H., Hattori N., Kubo S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
166. Shimura-Miura H., Hattori N., Kang D., et al. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol 46 (1999) 920-924
167. Sian J., Dexter D.T., Lees A.J., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36 (1994) 348-355
168. Sian J., Dexter D.T., Lees A.J., et al. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36 (1994) 356-361
169. Sofic E., Riederer P., Heinsen H., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74 (1988) 199-205
170. Sohmiya M., Tanaka M., Tak N.W., et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 223 (2004) 161-166
171. Spencer J.P., Jenner A., Aruoma O.I., et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353 (1994) 246-250
172. Spina M.B., and Cohen G. Hydrogen peroxide production in dopamine neurons. Basic Life Sci 49 (1988) 1011-1014
173. Spina M.B., and Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86 (1989) 1398-1400
174. Sriram S.R., Li X., Ko H.S., et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 14 (2005) 2571-2586
175. Stefanova N., Reindl M., Neumann M., et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166 (2005) 869-876
176. Stoy N., Mackay G.M., Forrest C.M., et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93 (2005) 611-623
177. Sulzer D., and Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1 (2000) 181-195
178. Swerdlow R.H., Parks J.K., Miller S.W., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40 (1996) 663-671
179. Teismann P., Tieu K., Choi D.K., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100 (2003) 5473-5478
180. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134 (2005) 109-118
181. Tieu K., Ischiropoulos H., and Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55 (2003) 329-335
182. Tretter L., and dam-Vizi V. Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J Neurosci 24 (2004) 7771-7778
183. Trimmer P.A., Borland M.K., Keeney P.M., et al. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 88 (2004) 800-812
184. Unterberger U., Voigtlander T., and Budka H. Pathogenesis of prion diseases. Acta Neuropathol (Berl) 109 (2005) 32-48
185. Valente E.M., bou-Sleiman P.M., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
186. Wang J., Xiong S., Xie C., et al. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93 (2005) 953-962
187. Wang J., Markesbery W.R., and Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96 (2006) 825-832
188. Warner D.S., Sheng H., and Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 207 (2004) 3221-3231
189. West A.B., Moore D.J., Biskup S., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102 (2005) 16842-16847
190. Xu J., Zhong N., Wang H., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14 (2005) 1231-1241
191. Yao D., Gu Z., Nakamura T., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 101 (2004) 10810-10814
192. Yoritaka A., Hattori N., Uchida K., et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93 (1996) 2696-2701
193. Yoritaka A., Hattori N., Mori H., et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci 148 (1997) 181-186
194. Yoshino H., Nakagawa-Hattori Y., Kondo T., et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 4 (1992) 27-34
195. Zecca L., Youdim M.B., Riederer P., et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
196. Zhang J., Perry G., Smith M.A., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154 (1999) 1423-1429
197. Zhang L., Shimoji M., Thomas B., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14 (2005) 2063-2073
198. Zimprich A., Biskup S., Leitner P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607